MBL Wealth LLC Has $1.30 Million Stake in Merck & Co., Inc. $MRK

MBL Wealth LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 75.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,356 shares of the company’s stock after purchasing an additional 5,316 shares during the period. MBL Wealth LLC’s holdings in Merck & Co., Inc. were worth $1,301,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MRK. Darwin Wealth Management LLC lifted its holdings in Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares during the period. Barnes Dennig Private Wealth Management LLC lifted its holdings in Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after buying an additional 266 shares during the period. United Financial Planning Group LLC acquired a new position in Merck & Co., Inc. in the third quarter valued at approximately $31,000. Evolution Wealth Management Inc. acquired a new position in Merck & Co., Inc. in the second quarter valued at approximately $31,000. Finally, Wealth Watch Advisors INC acquired a new position in Merck & Co., Inc. in the third quarter valued at approximately $34,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MRK has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a report on Friday, February 13th. Guggenheim increased their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a report on Friday, February 6th. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a report on Thursday, January 8th. Finally, Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $127.59.

Insiders Place Their Bets

In related news, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the transaction, the chief marketing officer owned 80,615 shares of the company’s stock, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president directly owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 320,176 shares of company stock valued at $38,281,735 in the last quarter. Company insiders own 0.09% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: JPMorgan raised its price target to $135 and kept an Overweight rating, signaling analyst confidence in MRK’s outlook and providing near-term upside support. Benzinga: JPMorgan raises price target
• Positive Sentiment: Quarterly strength is being highlighted by investors and funds (TCW note): strong Q4 results and continuing revenue/earnings momentum bolster the company’s fundamentals and dividend/total-return story. Strong Results Lifted Merck & Co (MRK) in Q4
• Positive Sentiment: Merck’s planned acquisition of Terns Pharmaceuticals adds early- and mid-stage oncology assets, helping replenish the pipeline ahead of Keytruda patent pressures — a strategic, long-term positive for oncology exposure. Merck’s Terns Deal Targets Cancer Pipeline And Keytruda Patent Risks
• Neutral Sentiment: Merck formally commenced a cash tender offer for Terns (deal mechanics underway); closing is expected in Q2 2026 subject to conditions — procedural step that keeps the acquisition on track. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Neutral Sentiment: Broader healthcare/M&A coverage notes an industry-wide pickup in transactions as peers bolster pipelines — a contextual tailwind but not company-specific. Pharma, Biotech Giants Ramp Up M&A in Q1
• Neutral Sentiment: General analyst/market commentary pieces and related biotech updates reference Merck as a defensive/dividend name, supporting its investor appeal but not changing near-term fundamentals. Analysts Offer Insights on Healthcare Companies: Merck (MRK)
• Negative Sentiment: Merck reportedly lowered its offer price for Terns after reviewing trial data, which may signal diligence concerns about the target’s assets and has likely created near?term investor uncertainty about deal value/benefit. Merck Lowered Terns Pharmaceuticals Offer Price
• Negative Sentiment: Short-term price weakness: coverage notes MRK shares declined while the broader market improved, suggesting profit-taking or deal-related jitters are weighing on the stock today. Merck (MRK) Stock Declines While Market Improves
• Negative Sentiment: Cautionary pieces ask whether defensive names like Merck are overbought after recent gains, which can pressure the stock if investors rotate out of healthcare. Is It Too Late to Buy Costco or Merck?

Merck & Co., Inc. Stock Down 1.6%

Shares of MRK stock opened at $118.91 on Wednesday. The firm has a fifty day moving average of $118.21 and a 200-day moving average of $103.93. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company has a market capitalization of $293.98 billion, a price-to-earnings ratio of 16.33, a P/E/G ratio of 2.44 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the prior year, the firm earned $1.72 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were given a $0.85 dividend. The ex-dividend date of this dividend was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.